10x Genomics (NASDAQ:TXG) Trading Down 5.5% Following Insider Selling

Shares of 10x Genomics (NASDAQ:TXG) fell 5.5% during trading on Tuesday after an insider sold shares in the company. The stock traded as low as $18.97 and last traded at $19.0240. 2,315,063 shares traded hands during mid-day trading, a decline of 28% from the average session volume of 3,233,625 shares. The stock had previously closed at $20.13.

Specifically, CEO Serge Saxonov sold 13,261 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $251,959.00. Following the transaction, the chief executive officer owned 1,021,556 shares in the company, valued at approximately $19,409,564. This represents a 1.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 8,283 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $157,377.00. Following the sale, the insider owned 432,605 shares of the company’s stock, valued at approximately $8,219,495. This represents a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In other 10x Genomics news, CFO Adam Taich sold 11,888 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $225,872.00. Following the transaction, the chief financial officer directly owned 297,385 shares of the company’s stock, valued at $5,650,315. This represents a 3.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Wall Street Zen downgraded 10x Genomics from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research report on Monday, November 17th. Barclays boosted their price objective on shares of 10x Genomics from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. UBS Group raised their target price on shares of 10x Genomics from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 target price on shares of 10x Genomics and gave the stock a “hold” rating in a research report on Friday, August 8th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $14.88.

10x Genomics Price Performance

The stock’s 50 day simple moving average is $13.79 and its two-hundred day simple moving average is $12.56. The company has a market capitalization of $2.37 billion, a P/E ratio of -30.24 and a beta of 2.13.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05. The company had revenue of $149.00 million for the quarter, compared to the consensus estimate of $142.50 million. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The company’s revenue was down 1.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.30) EPS. 10x Genomics has set its Q4 2025 guidance at EPS. As a group, equities research analysts expect that 10x Genomics will post -1.43 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Amundi grew its stake in shares of 10x Genomics by 16,013.7% during the 1st quarter. Amundi now owns 320,340 shares of the company’s stock worth $2,553,000 after acquiring an additional 318,352 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in 10x Genomics by 163.5% during the first quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company’s stock worth $5,634,000 after purchasing an additional 400,430 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in 10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock worth $62,016,000 after purchasing an additional 4,987,195 shares during the last quarter. Pallas Capital Advisors LLC grew its position in 10x Genomics by 138.8% in the second quarter. Pallas Capital Advisors LLC now owns 56,776 shares of the company’s stock valued at $657,000 after purchasing an additional 32,996 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC acquired a new stake in 10x Genomics in the 2nd quarter valued at $906,000. Institutional investors own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.